- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
ICON PLC (ICLR)
ICON PLC stock price live, this page displays NASDAQ ICLR stock exchange data. View the ICLR premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the ICON PLC real time stock price chart below.
What Is the ICON PLC Stock Price Today?
The ICON PLC stock price today is 169.86.
What Is the Stock Symbol for ICON PLC?
The stock symbol for ICON PLC is "ICLR."
What Stock Exchange Does ICON PLC Trade On?
ICON PLC is listed and trades on the NASDAQ stock exchange.
Is ICON PLC a Good Stock to Buy?
Determining whether ICON PLC—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ICLR quote. (ISIN: IE0005711209)
What Is the ICON PLC Stock Price Today?
The ICON PLC stock price today is 169.86.
What Is the Stock Symbol for ICON PLC?
The stock symbol for ICON PLC is "ICLR."
What Stock Exchange Does ICON PLC Trade On?
ICON PLC is listed and trades on the NASDAQ stock exchange.
Is ICON PLC a Good Stock to Buy?
Determining whether ICON PLC—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ICLR quote. (ISIN: IE0005711209)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
158.59
170.51
52 wk Range
66.57
211.00
ICLR is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
158.59170.51
52 wk Range
66.57211.00
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
ICLR Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Price Target
175.31
Upside
+3.21%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Net income is expected to grow this year
- ICON Plc receives Investment Bank Analyst Rating Update
- Investing.com
Pro - ICON Plc receives Investment Bank Analyst Rating Update
- Investing.com
Pro - ICON Plc receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- ICON Plc receives Investment Bank Analyst Rating Update
- Investing.com
Pro - ICON Plc receives Investment Bank Analyst Rating Update
- Investing.com
Pro - ICON Plc receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Analyst Ratings
9 Buy
7 Hold
1 Sell
Ratings:
17 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 175.31
(+3.21% Upside)
ICON PLC SWOT Analysis
CRO Market Dynamics | Explore ICON's navigation of industry challenges, including bookings volatility and demand uncertainties in the competitive CRO landscape |
Financial Resilience | Delve into ICON's solid financial health, with EPS forecasts of $13.40 (FY1) and $14.06 (FY2), despite recent market pressures |
Strategic Positioning | Learn how ICON leverages proprietary technology and global scale to capture high-quality opportunities in a shifting pharmaceutical landscape |
Valuation Insights | Analysts set price targets ranging from $155 to $263, suggesting potential for value realization as transient headwinds subside |
ICON PLC Earnings Call Summary for Q1/2026
- ICON Q1 2026 revenue hit $2.11B, beating estimates by 7.65%, while adjusted EPS of $2.52 missed forecasts by 16% amid margin pressure.
- Shares surged 20% after-hours on strong bookings of $3.3B and net book-to-bill of 1.42x, signaling improved commercial momentum across pharma segments.
- Adjusted EBITDA margin fell to 15.6% from 19.8% YoY due to mix shift toward lower-margin services, FX headwinds, and pricing pressures.
- Management maintained full-year 2026 guidance of $7.85B-$8.15B revenue and $10-$11 EPS, expecting Q2 EBITDA margin to improve to ~16%.
- CFO Clerkin confirmed share buybacks remain capital allocation priority while CEO Balfe emphasized focus on pipeline quality and profitability.
Last Updated: 06/24/2026, 09:20 PM
Read Full TranscriptEarnings
Latest Release
May 27, 2026
EPS / Forecast
2.52 / 3.00
Revenue / Forecast
2.11B / 1.96B
Compare ICLR to Peers and Sector
Metrics to compare | ICLR | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipICLRPeersSector | |
|---|---|---|---|---|
P/E Ratio | 75.1x | 25.0x | −0.4x | |
PEG Ratio | −0.99 | 0.00 | 0.00 | |
Price/Book | 1.4x | 2.7x | 2.6x | |
Price / LTM Sales | 1.6x | 3.0x | 3.0x | |
Upside (Analyst Target) | 4.5% | 18.0% | 57.0% | |
Fair Value Upside | Unlock | 16.3% | 9.1% | Unlock |
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, contract staffing, data solutions, and laboratory services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company offers testing services comprising bioanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, the company provides adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, medical imaging, real world intelligence, site and patient, and strategic solutions. Additionally, it provides therapeutics for cardiovascular, central nervous system, endocrine and metabolic disorders, hepatology, infectious diseases, internal medicine immunology, and oncology. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. ICON Public Limited Company was incorporated in 1989 and is headquartered in Dublin, Ireland.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the ICON PLC (ICLR) Stock Price Today?
The ICON PLC stock price today is 169.86 USD.
What Stock Exchange Does ICON PLC Trade On?
ICON PLC is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for ICON PLC?
The stock symbol for ICON PLC is "ICLR."
What Is the ICON PLC Market Cap?
As of today, ICON PLC market cap is 13.01B USD.
What Is ICON PLC's Earnings Per Share (TTM)?
The ICON PLC EPS (TTM) is 2.24.
When Is the Next ICON PLC Earnings Date?
ICON PLC will release its next earnings report on Jul 29, 2026.
From a Technical Analysis Perspective, Is ICLR a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has ICON PLC Stock Split?
ICON PLC has split 2 times.
How Many Employees Does ICON PLC Have?
ICON PLC has 40350 employees.
What is the current trading status of ICON PLC (ICLR)?
As of Jun 29, 2026, ICON PLC (ICLR) is trading at a price of 169.86 USD, with a previous close of 160.96 USD. The stock has fluctuated within a day range of 158.59 USD to 170.51 USD, while its 52-week range spans from 66.57 USD to 211.00 USD.
What Is ICON PLC (ICLR) Price Target According to Analysts?
The average 12-month price target for ICON PLC is 175.31 USD, with a high estimate of 197 USD and a low estimate of 150 USD. 9 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +3.21% Upside potential.
What Is the ICLR Premarket Price?
ICLR's last pre-market stock price is 160.88 USD. The pre-market share volume is 90.00, and the stock has decreased by -0.08, or -0.05%.
What Is the ICLR After Hours Price?
ICLR's last after hours stock price is 171.99 USD, the stock has decreased by 2.13, or 1.25%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.